A Guide To The Risks Of Investing In Aptose Biosciences Inc. (APTO)

CHWY Stock
CHWY Stock

Aptose Biosciences Inc.’s filing revealed that its Chair, President & CEO Rice William G. acquired Company’s shares for reported $6834.0 on Sep 19. In the deal valued at $0.68 per share,10,000 shares were bought. As a result of this transaction, Rice William G. now holds 363,252 shares worth roughly $ 0.28 million.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Then, Payne Fletcher bought 10,000 shares, generating $6,775 in total proceeds. Upon buying the shares at $0.68, the SR VP & Chief Fin. Officer now owns 10,000 shares.

Before that, Rice William G. bought 10,000 shares. Aptose Biosciences Inc. shares valued at $9,681 were divested by the Chair, President & CEO at a price of $0.97 per share. As a result of the transaction, Rice William G. now holds 353,252 shares, worth roughly $0.27 million.

Cantor Fitzgerald initiated its Aptose Biosciences Inc. [APTO] rating to an Overweight in a research note published on Monday, October 19, 2020; the price target was $10. PT values the company’s stock at a premium of 92.4 to its Monday closing price. A number of analysts have revised their coverage, including Alliance Global Partners’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. Maxim Group began covering APTO with “Buy” recommendation on February 20, 2020. H.C. Wainwright maintained its rating on February 06, 2020. It rated APTO as “a Buy”.

Price Performance Review of APTO

On Monday, Aptose Biosciences Inc. [NASDAQ:APTO] saw its stock jump 11.76% to $0.76. On the same session, the stock had its day’s lowest price of $0.6801, but rose to a high of $0.7899. Over the last five days, the stock has gained 65.04%. Aptose Biosciences Inc. shares have fallen nearly -43.70% since the year began. Nevertheless, the stocks have fallen -68.85% over the past one year. While a 52-week high of $2.78 was reached on 04/04/22, a 52-week low of $0.45 was recorded on 10/31/22. SMA at 50 days reached $0.6178, while 200 days put it at $0.9332. A total of 0.89 million shares were traded, compared to the trading of 1.99 million shares in the previous session.

Levels Of Support And Resistance For APTO Stock

The 24-hour chart illustrates a support level at 0.6968, which if violated will result in even more drops to 0.6335. On the upside, there is a resistance level at 0.8066. A further resistance level may holdings at 0.8531. The Relative Strength Index (RSI) on the 14-day chart is 70.58, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1807, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 8.82%. Stochastics %K at 87.41% indicates the stock is a selling.

How much short interest is there in Aptose Biosciences Inc.?

A steep rise in short interest was recorded in Aptose Biosciences Inc. stocks on Jul 14, 2022, dropping by -0.15 million shares to a total of 0.27 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 0.41 million shares. There was a decline of -54.38%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.29% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.29.

The most recent change occurred on January 09, 2020 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $10 price target.


Please enter your comment!
Please enter your name here